UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 14, 2016
DICERNA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36281 | 20-5993609 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
87 Cambridgepark Drive
Cambridge, MA 02140
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (617) 621-8097
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c)) |
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 18, 2016, Dicerna Pharmaceuticals, Inc. (the Company) announced that John Jack Green, the Companys interim Chief Financial Officer, entered into an amended and restated employment agreement (the Employment Agreement) to become the Companys full time Chief Financial Officer. In this role, Mr. Green will continue to serve as the Companys principal financial officer.
Mr. Green, 62, is a certified public accountant with over 30 years of financial management experience, including more than 20 years within the biotechnology sector. Mr. Green has served as the Companys interim Chief Financial Officer since January 2016. Prior to joining the Company, Mr. Green was Chief Financial Officer of Verastem, Inc. from May 2013 to April 2016. Prior to joining Verastem, Inc., from March 2011 until December 2012, Mr. Green was Vice President, Finance of On-Q-ity Inc. Prior to that, from May 2002 until June 2010, Mr. Green was the Senior Vice President and Chief Financial Officer of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation). Mr. Green holds a masters degree in business administration from Boston University Graduate School of Management and a bachelors degree from College of the Holy Cross.
Mr. Greens Employment Agreement is effective as of April 14, 2016 and provides, among other things, that as compensation for his services as CFO, Mr. Green will receive an annual base salary initially established at $350,000 and will be eligible for an annual incentive bonus, with his initial target bonus being 40% percent of his base salary. The Board of Directors of the Company will determine Mr. Greens actual bonus amount based on an assessment of the performance of the Company and Mr. Green during the year. The Employment Agreement also provides for Mr. Green to receive a stock option to purchase up to 265,000 shares of common stock of the Company at an exercise price equal to the closing price of the common stock on the date of grant. The option will vest over a four-year period, subject to Mr. Greens continued employment through each vesting date. This option is subject to the terms of the Companys Amended and Restated 2014 Performance Incentive Plan. The Employment Agreement also provides for Mr. Green to participate in the Companys benefit programs made available to its senior executives generally. Mr. Green has entered into the Companys standard form of indemnification agreement which provides, among other things, that the Company will indemnify Mr. Green, under the circumstances and to the extent provided for therein, for certain expenses which he may be required to pay in connection with certain claims to which he may be made a party by reason of his position as an officer of the Company, and otherwise to the fullest extent permitted under Delaware law and the Companys Bylaws. Mr. Green does not have any family relationship required to be reported pursuant to Item 401(d) or have or had any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K.
Under the Employment Agreement, if Mr. Greens employment is terminated by the Company without Cause or by him for Good Reason (as such terms are defined in the agreement), he will be entitled to receive cash severance equal to 12 months of his base salary, payment of a pro-rata portion of his annual bonus, and reimbursement of his COBRA premiums for up to 12 months. If such a termination occurs within one year after a change in control of the Company, in addition to the foregoing benefits, any equity awards granted to Mr. Green will vest in full. Mr. Greens right to receive these severance benefits is subject to his providing a release of claims in favor of the Company.
The foregoing description of Mr. Greens employment terms is a summary only and is qualified in its entirety by reference to the full text of the Employment Agreement, which will be filed as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
The Company hereby incorporates by reference the information relating to the appointment of Mr. Green set forth in the press release issued on April 18, 2016, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibit
Exhibit No. |
Description | |
99.1 | Press release titled Dicerna Announces Appointment of John Jack Green as Chief Financial Officer issued by Dicerna Pharmaceuticals, Inc. on April 18, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 18, 2016 | DICERNA PHARMACEUTICALS, INC. | |||||
By: | /s/ Douglas M. Fambrough, III, Ph.D. | |||||
Douglas M. Fambrough, III, Ph.D. | ||||||
Chief Executive Officer |
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | Press release titled Dicerna Announces Appointment of John Jack Green as Chief Financial Officer issued by Dicerna Pharmaceuticals, Inc. on April 18, 2016 |
Exhibit 99.1
Dicerna Announces Appointment of John Jack Green as Chief Financial Officer
CAMBRIDGE, Mass., (April 18, 2016) Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. Jack Green as chief financial officer (CFO), effective immediately. Mr. Green has served as the Companys interim CFO since January 2016.
I am very pleased to announce Jack as permanent CFO, as he brings to Dicerna a wealth of knowledge in finance and a strong track-record with public biotech companies, said Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna. Since joining the Company as interim CFO, Jacks strategic and business insights have added tremendous value and will be instrumental to the continued growth of Dicerna.
Mr. Green is a certified public accountant with over 30 years of financial management experience, including more than 20 years within the biotechnology sector. Prior to joining Dicerna as CFO, he served as CFO of Verastem, Inc. (VSTM). Previously, he served for more than 15 years as CFO of GTC Biotherapeutics (formerly Genzyme Transgenics), a publicly-traded biotechnology company spun out of Genzyme as a stand-alone company in 1993. Mr. Green received a Master of Business Administration from Boston University Graduate School of Management and a Bachelor of Arts from the College of the Holy Cross.
Dicerna has made great progress developing an exciting pipeline of clinical-stage oncology and rare disease product candidates as well as an emerging pipeline of DsiRNA-EX conjugate programs for liver-targeted diseases, said Mr. Green. I look forward to contributing to Dicernas success as we advance these programs through clinical development and to working closely with the management team and Board of Directors.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver, for other therapeutic areas in which the liver plays a key role, and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In many cases, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional
approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop, and commercialize these novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical and clinical research and other risks identified under the heading Risk Factors included in our most recent Form 10-K filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicernas current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Investor Contact:
Rx Communications Group, LLC
Melody Carey, 917-322-2571
mcarey@rxir.com
Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com
2